- SFG FRC 2027 | Program starts from 19th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
Source: The post is based on the article “Medicines Patent Pool deal to make cancer drug cheaper” published in The Hindu on 23rd June 2023
What is the News?
The Medicines Patent Pool (MPP) has signed sub-licence agreements with India-based companies, along with an Indonesian firm, to make generic versions of the drug Nilotinib of the Switzerland-based pharmaceutical corporation Novartis.
What is Nilotinib?
Nilotinib is used for the treatment of chronic myeloid leukaemia, a type of blood cancer. Nilotinib is sold under the brand name Tasigna and marketed worldwide by Novartis.
What is the significance of agreement for making generic versions of Nilotinib?
Under the agreement, selected manufacturers can make generic versions of Nilotinib in India and seven middle-income countries.
They can also supply it in 44 territories included in the licence through a non-exclusive licence agreement, subject to local regulatory authorisation.
The move will give an affordable treatment option to people diagnosed with the disease in such countries. This will make certain cancer drugs more accessible and cheaper for patients.
| Read more: All That India Can Do To Make Cancer A Less Dismal State |
What is Medicines Patent Pool (MPP)?
MPP is a United Nations-backed group working towards increasing access to, and facilitating the development of, life-saving medicines for low- and middle-income countries.
MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
